EDVAConsumer Defensive · Beverages - Wineries & DistilleriesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 12 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Endovia Health Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EDVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Sept 2024 | Roth MKM | Maintains | Buy | — |
| 26 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 June 2024 | Roth MKM | Maintains | Buy | — |
| 22 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Nov 2023 | EF Hutton | Reiterates | Buy | — |
| 14 Sept 2023 | EF Hutton | Reiterates | Buy | — |
| 16 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | EF Hutton | Maintains | Buy | — |
| 27 June 2023 | Roth MKM | Initiates | Buy | — |
| 7 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Feb 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Apr 2022 | EF Hutton | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EDVA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Endovia Health Sciences, Inc. returned −96.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 2% of US stocks
Cheaper than 93% of US stocks
Cheaper than 65% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 54% of US stocks
Higher than 1% of US stocks
Higher than 85% of US stocks
Higher than 98% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Endovia Health Sciences, Inc. has a market value of $1.6M and an enterprise value of $8.6M.
Revenue in the twelve months to 30 June 2026: −$361K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$17.3M, a 4787.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.5M.
Trailing P/E: −0.0×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Endovia Health Sciences, Inc. employs 1 people — −$361K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| EDVAEndovia Health Sciences, Inc. | $1.6M | 3 |
| IBGInnovation Beverage Group Ltd. | $1.7M | 3 |
| YHCLQR House, Inc. | $1.8M | 7 |
| EPSMEpsium Enterprise Ltd. | $3.6M | 5 |
| AMSSAMASS Brands, Inc. | $8.1M | 2 |
| WVVIWillamette Valley Vineyards, Inc. | $10.5M | 39 |
| BIOTInstinct Bio Technical Co. Holdings, Inc.* | $1.6M | 31 |
* Nearest Consumer Defensive names by size — few beverages - wineries & distilleries companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Endovia Health Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Splash Beverage Group announced its corporate name will change to Endovia Health Sciences, Inc. Effective at market open Monday, its common stock will trade on NYSE American under the new ticker symbol "EDVA."
Why it matters — SBEV watchers will need to track the company under its new name and the new ticker symbol "EDVA" starting Monday.
Splash Beverage Group reported its financial results for the second quarter ended June 30, 2026, and provided an update on its ongoing strategic transformation toward Endovia Health Sciences.
Why it matters — SBEV watchers would care because this update confirms the company's continued shift toward its Endovia Health Sciences strategy alongside its quarterly results.
Splash Beverage Group announced it will change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026.
Why it matters — The rebranding signals a shift in corporate identity that SBEV shareholders will want to monitor for potential changes in business direction.
Splash Beverage Group has signed a strategic development and collaboration agreement with Lupvindol Biosciences to advance CannEpil® through the FDA veterinary pathway, initially focusing on oncology and chronic pain management in companion animals. Splash retains ownership of resulting data, intellectual property, and commercialization rights.
Why it matters — SBEV watchers would care because this partnership expands Splash's pipeline into the veterinary cannabinoid drug market while preserving full ownership of the resulting intellectual property and commercialization rights.
Splash Beverage Group has expanded its exclusive global license for CannEpil® to include veterinary applications, establishing a second FDA-regulated pharmaceutical development program.
Why it matters — This move gives SBEV a second regulated pharmaceutical platform beyond human therapeutics, broadening its development pipeline into the veterinary market.
Of the 1 analysts covering Endovia Health Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Endovia Health Sciences, Inc. 3 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Endovia Health Sciences, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No analyst covering Endovia Health Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDVA are extrapolating price history, which says nothing about the business.
Endovia Health Sciences, Inc. returned -96.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Endovia Health Sciences, Inc. is a health sciences company focused on cannabinoid-based pharmaceutical, veterinary, and consumer wellness products.
The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday". Splash Beverage Group announced its corporate name will change to Endovia Health Sciences, Inc. Effective at market open Monday, its common stock will trade on NYSE American under the new ticker symbol "EDVA."
Endovia Health Sciences, Inc. is a health sciences company focused on cannabinoid-based pharmaceutical, veterinary, and consumer wellness products. The company develops and commercializes differentiated health technologies across regulated human and animal health markets, with current emphasis on commercial pharmaceutical assets and FDA-regulated therapeutics. Its portfolio includes cannabinoid-based programs such as CannEpil®, which is being advanced for veterinary applications, alongside wellness-oriented offerings that extend its reach into consumer-facing health categories. Endovia Health Sciences operates as a diversified platform that combines product development, regulatory work, and market commercialization across multiple segments of the cannabinoid industry. The company serves markets that include pharmaceuticals, companion-animal health, and wellness products, positioning it as a specialized participant in emerging cannabinoid healthcare applications.
CEO Mr. Robert Nistico · 1 employees · United States · https://splashbeveragegroup.com
